Document Detail


Erectile dysfunction following prostatectomy: prevention and treatment.
MedLine Citation:
PMID:  19657376     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Radical prostatectomy (RP) remains the standard treatment for men with clinically localized prostate cancer, despite the range of alternative treatment modalities. Even with significant advances in surgical technique and superb results for cancer control and preservation of urinary function, erectile dysfunction (ED) following RP is a common complication. This is mainly attributed to temporary cavernous nerve damage (neuropraxia) resulting in penile hypoxia, smooth muscle apoptosis, fibrosis and veno-occlusive dysfunction. One of the most promising new approaches is the concept of early penile rehabilitation, which is thought to prevent ED after RP by countering post-RP pathophysiological changes during the period of neural recovery. Various treatments, such as vacuum constriction devices, intraurethral and intracorporal alprostadil, and phosphodiesterase type 5 (PDE5) inhibitors, might serve to facilitate recovery of erectile function. PDE5 inhibitors are considered as the first-line treatment for early penile rehabilitation, with superior erectile function outcomes compared to placebo. Definitive conclusions regarding the success of penile rehabilitation cannot be drawn at this time because of differences in study design, data acquisition, and definitions of potency. Continued prospective, rigorous study is needed to develop and bring forward this important field and to establish the best evidence basis for counseling and treating patients suffering from ED after RP.
Authors:
Ahmed Magheli; Arthur L Burnett
Related Documents :
16194716 - Holmium laser enucleation of the prostate: a size-independent new "gold standard".
12441946 - A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in pat...
3599226 - Antibiotic prophylaxis of urinary tract infection after transurethral resection of the ...
17206906 - Treatment characteristics and inherent prostatic features do not predict patient outcom...
22366106 - Effect of early ambulation after transfemoral cardiac catheterization in hong kong: a s...
11251266 - Outcome following tricuspid valve detachment for ventricular septal defects closure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature reviews. Urology     Volume:  6     ISSN:  1759-4820     ISO Abbreviation:  Nat Rev Urol     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-06     Completed Date:  2010-04-19     Revised Date:  2011-07-19    
Medline Journal Info:
Nlm Unique ID:  101500082     Medline TA:  Nat Rev Urol     Country:  England    
Other Details:
Languages:  eng     Pagination:  415-27     Citation Subset:  IM    
Affiliation:
Department of Urology, Charité University Medicine Berlin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Erectile Dysfunction / etiology,  prevention & control*,  therapy*
Humans
Male
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors / pharmacology,  therapeutic use
Prostatectomy / adverse effects*
Prostatic Neoplasms / physiopathology,  surgery
Treatment Outcome
Chemical
Reg. No./Substance:
0/Phosphodiesterase 5 Inhibitors; 0/Phosphodiesterase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What is microbial community ecology?
Next Document:  ETS gene fusions in prostate cancer.